Gavin Clark-Gartner
Stock Analyst at Evercore ISI Group
(1.88)
# 3,148
Out of 4,911 analysts
30
Total ratings
42.31%
Success rate
-9.29%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Gavin Clark-Gartner
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| JSPR Jasper Therapeutics | Maintains: Outperform | $50 → $20 | $3.13 | +538.98% | 3 | Jul 8, 2025 | |
| PRQR ProQR Therapeutics | Initiates: Outperform | $5 | $2.26 | +121.73% | 1 | Apr 29, 2025 | |
| ABBV AbbVie | Maintains: Outperform | $204 → $205 | $190.83 | +7.43% | 3 | Apr 28, 2025 | |
| MNMD Mind Medicine (MindMed) | Initiates: Outperform | $23 | $9.72 | +136.63% | 1 | Jan 28, 2025 | |
| CABA Cabaletta Bio | Downgrades: In-Line | $15 → $6 | $1.66 | +261.45% | 2 | Dec 20, 2024 | |
| ARGX argenx SE | Maintains: Outperform | $675 → $706 | $591.74 | +19.31% | 4 | Nov 21, 2024 | |
| SRPT Sarepta Therapeutics | Maintains: Outperform | $179 → $170 | $12.88 | +1,219.88% | 9 | Nov 7, 2024 | |
| FHTX Foghorn Therapeutics | Initiates: Outperform | $20 | $6.19 | +223.10% | 1 | Aug 19, 2024 | |
| KRYS Krystal Biotech | Maintains: Outperform | $201 → $206 | $150.00 | +37.33% | 1 | Aug 12, 2024 | |
| MIRM Mirum Pharmaceuticals | Maintains: Outperform | $62 → $66 | $52.17 | +26.51% | 2 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $22 | $1.68 | +1,209.52% | 1 | Oct 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $20 → $10 | $2.29 | +336.68% | 1 | May 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $54 → $60 | $23.07 | +160.08% | 1 | Oct 5, 2022 |
Jasper Therapeutics
Jul 8, 2025
Maintains: Outperform
Price Target: $50 → $20
Current: $3.13
Upside: +538.98%
ProQR Therapeutics
Apr 29, 2025
Initiates: Outperform
Price Target: $5
Current: $2.26
Upside: +121.73%
AbbVie
Apr 28, 2025
Maintains: Outperform
Price Target: $204 → $205
Current: $190.83
Upside: +7.43%
Mind Medicine (MindMed)
Jan 28, 2025
Initiates: Outperform
Price Target: $23
Current: $9.72
Upside: +136.63%
Cabaletta Bio
Dec 20, 2024
Downgrades: In-Line
Price Target: $15 → $6
Current: $1.66
Upside: +261.45%
argenx SE
Nov 21, 2024
Maintains: Outperform
Price Target: $675 → $706
Current: $591.74
Upside: +19.31%
Sarepta Therapeutics
Nov 7, 2024
Maintains: Outperform
Price Target: $179 → $170
Current: $12.88
Upside: +1,219.88%
Foghorn Therapeutics
Aug 19, 2024
Initiates: Outperform
Price Target: $20
Current: $6.19
Upside: +223.10%
Krystal Biotech
Aug 12, 2024
Maintains: Outperform
Price Target: $201 → $206
Current: $150.00
Upside: +37.33%
Mirum Pharmaceuticals
Aug 8, 2024
Maintains: Outperform
Price Target: $62 → $66
Current: $52.17
Upside: +26.51%
Oct 3, 2023
Initiates: Outperform
Price Target: $22
Current: $1.68
Upside: +1,209.52%
May 30, 2023
Maintains: Outperform
Price Target: $20 → $10
Current: $2.29
Upside: +336.68%
Oct 5, 2022
Maintains: Outperform
Price Target: $54 → $60
Current: $23.07
Upside: +160.08%